AB Science is hosting live webcast on Monday May 11, 2020 on masitinib in combination with isoquercetine for the treatment of COVID-19

Paris, May 07, 2020, 7pm

AB Science is hosting live webcast on Monday May 11, 2020 on masitinib
in combination with isoquercetine for the treatment of COVID-19

AB Science SA (NYSE Euronext - FR0010557264 - AB) will host a live webcast on Monday 11, 2020 following the recent authorization by the French Medicine Agency, ANSM, to initiate a Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19.

This study (AB20001) is a randomized (1:1), open-label Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The study will enroll 200 patients (age ≥18 without an upper age limit) at medical centers in France and other countries. The primary objective is to improve the clinical status of patients after 15 days of treatment.

This webcast will feature a presentation by AB Science's management team and Jean-Pierre Kinet, Co-President of AB Science Scientific Committee and will present the detailed study design and further explain the scientific rationale for combining masitinib with isoquercetin.

Dial-In & Webcast Information

Webcast date: Monday, May 11, 2020. USA: 11:30am EST; Europe 5:30pm CET
Number for the US: [phone]
Number for France: [phone]
International numbers (outside US and France): Numbers for other countries are listed on the webcast page
Conference ID: 77816444#

Webcast and replay here

Jean-Pierre Kinet biography

Professor Jean-Pierre Kinet, M.D., is one of the most prominent immunology experts worldwide, most famous for discovering some of the genes and proteins constituting the immunoglobulin E receptor. These scientific breakthroughs contributed to the introduction of new diagnostic tools and therapies for diseases related to immune system dysregulation. He also is the co-founder and founder of two biotech companies (AB Science and Astarix), and is a board member of several other biotech companies in Europe.

He is Professor of Pathology at Harvard Medical School (Boston – USA). He is also a member of National Institute of Health (NIH) expert panels, and of the medical Board of the American Asthma Foundation in the USA.  Jean-Pierre Kinet is a member of the Scientific Advisory Board of UCB Pharma and Managing Partner of iXLife Capital. Jean-Pierre Kinet received his medical degree from the University of Liege (Belgium), and was trained in internal medicine at the Liège University hospital. He has written over 200 publications and holds 10 American and global patents. In 1997, he received the “NIH Inventor Award” and in 2004 the prestigious “NIH Merit Award”.